top of page
< Back

Ibrutinib

依布替尼

Mechanism of action:

Ibrutinib 是一種布魯頓酪胺酸激酶抑制劑（Bruton's tyrosine kinase inhibitor）。Ibrutinib 會共價鍵結合並抑制布魯頓酪胺酸激酶（Bruton's tyrosine kinase）的活性，阻斷下游的 NF-κB、PI3K-AKT、MAPK 路徑，最終抑制 B 細胞受體（BCR）相關存活與增殖訊號。

​Reference(s):

1. Bagcchi S et al. (2015). Ibrutinib in pretreated Waldenstrom's macroglobulinaemia. Lancet Oncol. 


2. Kim ES et al. (2015). Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 


3. Scheers E et al. (2015). Absorption, metabolism, and excretion of oral ¹⁴C-radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos.

bottom of page